As biosimilar etanercept SB4, sold in many markets as Benepali, has entered the rheumatoid arthritis treatment space, researchers have recognized the need to investigate the retention rates and disease activity scores among patients receiving SB4 and its reference.
As biosimilar etanercept SB4, sold in many markets as Benepali, has entered the rheumatoid arthritis (RA) treatment space, researchers have recognized the need to investigate the retention rates and disease activity scores among patients receiving SB4 and its reference product.
In a study1 presented at the American College of Rheumatology’s (ACRs) Annual Meeting in Chicago, Illinois, researchers will report on their study that compared treatment survival on etanercept biosimilar SB4 with treatment survival on the reference product using real-world data.
Data were collected from 2015-2018 from patients with RA who began treatment with SB4 or the reference product and who had at least 1 followup visit. Drug survival rates during the first 6 months were analyzed using Kaplan-Meier curves.
In total, 266 patients were treated with SB4 compared with 313 patients administered the reference product. Researchers found that those taking SB4 had a shorter disease duration (7.5 years versus 8.7 years, respectively) and were younger (58 years of age versus 59 years of age, respectively). Fewer patients taking SB4 than the reference had 3 or more comorbidities (39% versus 47%, respectively). In addition, the Kaplan-Meier curves showed higher retention rates over 6 months for SB4 than the reference.
The most frequent reasons for discontinuation of either treatment were adverse events (48% in the SB4 arm and 54% in the reference arm) and ineffectiveness (36% of the SB4 arm and 36% of the reference arm).
The study’s authors concluded that higher retention rates were identified for patients starting biosimilar SB4 compared with those beginning with the originator product.
A second study addressing SB42 that will be presented the meeting evaluated patients’ disease activity after switching from the originator etanercept to SB4. The study was conducted retrospectively across hospitals in Wales, United Kingdom.
To evaluate the disease activity before and after switching, investigators used the disease activity score in a count of 28 joints (DAS28) with C-reactive protein (CRP). The study found that after switching to the biosimilar, 39% of patients had an increase in their DAS28-CRP score.
Out of 102 patients who were in remission at the time of switching, 17% developed low, moderate, or high disease activity. At baseline, 18 patients had low or moderate disease activity, and 56% of this group moved to moderate or high disease activity.
Overall, the researchers noted that, while many patients enrolled in the study saw an increase in disease activity, it was deemed likely that these patients were not truly in disease remission at the time of switching. This finding suggests that the increase may be due to natural fluctuation or spontaneous disease flare in patients with unstable disease.
References
1. Baganz L, Meißner Y, Herzer P, et al. Treatment continuation on the etanercept original in comparison with a biosimilar. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2512. https://acrabstracts.org/abstract/treatment-continuation-on-the-etanercept-original-in-comparison-with-a-biosimilar/.
2. Rajamani K, Choy E. Change in disease activity after switching etanercept (originator) to biosimilar (Benepali) is associated with active disease at baseline. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2513. https://acrabstracts.org/abstract/change-in-disease-activity-after-switching-etanercept-originator-to-biosimilar-benepali-is-associated-with-active-disease-at-baseline/.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.